Media Centre
Latest press releases
-
Update following MHRA and EMA decisions on AstraZeneca’s COVID-19 vaccine
-
AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis
-
UK and EU regulatory agencies confirm COVID-19 Vaccine AstraZeneca is safe and effective
-
AstraZeneca concluye acuerdo para el suministro de la vacuna AZD1222 contra COVID-19 a Costa Rica
-
Statement on AstraZeneca Oxford SARS-CoV-2 vaccine, AZD1222, COVID-19 vaccine trials temporary pause
Contact Us
If you have any questions you can contact us by email:
Mónica Solórzano Lobo:
monica.solorzano1@astrazeneca.com
External Affairs and Communications Lead Central American and Caribbean, AstraZeneca